fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

How ovarian cancer defies immunotherapy

Written by | 12 Apr 2022

Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and… read more.

Researchers shorten manufacturing time for CAR T cell therapy

Written by | 1 Apr 2022

A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack… read more.

Lab results show promise for future pancreatic cancer treatment

Written by | 13 Feb 2022

University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.

Stem-like T cells could aid immunotherapy in cancer treatment

Written by | 12 Sep 2021

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.

Researchers develop novel strategy for tuberculosis vaccine

Written by | 29 Aug 2021

Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis. Mycobacterium tuberculosis (Mtb)… read more.

Investigative immunotherapy for multiple myeloma produces deep and durable response

Written by | 25 Aug 2021

One infusion of an investigative chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for multiple myeloma has produced early and durable responses in heavily pretreated patients, researchers reported… read more.

Protein disguise could be new target for cancer immunotherapy

Written by | 21 Jun 2021

Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer… read more.

Targeted drug combination improves survival in advanced kidney cancer

Written by | 24 Feb 2021

Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.

FDA approves Libtayo as first immunotherapy indicated for patients with advanced basal cell carcinoma – Sanofi

Written by | 19 Feb 2021

The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from Sanofi as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a… read more.

Immunotherapy vs chemotherapy for lung cancer: 5-year survival

Written by | 1 Feb 2021

Interview and article by Christine Clark IMI interviewed Dr Erin Schenk, Assistant Professor, Thoracic Oncology, University of Colorado to find out about key trial results in lung cancer… read more.

Immuno suppressing drugs do not increase risk for COVID-19

Written by | 25 Sep 2020

Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their… read more.

Optimal delivery of immunotherapy in advanced NSCLC

Written by | 11 Nov 2019

Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.